|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:administeredBy
|
Diskhaler device
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AH01
|
|
gptkbp:brand
|
gptkb:Relenza
|
|
gptkbp:CASNumber
|
139110-80-8
|
|
gptkbp:chemicalClass
|
sialic acid analog
|
|
gptkbp:contraindication
|
asthma
chronic obstructive pulmonary disease
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
2.5-5.1 hours
|
|
gptkbp:firstBook
|
neuraminidase inhibitor
|
|
gptkbp:form
|
powder for inhalation
|
|
gptkbp:genericName
|
gptkb:zanamivir
|
|
gptkbp:hasMolecularFormula
|
C12H20N4O7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Relenza
|
|
gptkbp:KEGGID
|
D08437
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
neuraminidase inhibitor
|
|
gptkbp:molecularWeight
|
332.31 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:PubChem_CID
|
54810
60855
DB00558
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
headache
cough
bronchospasm
|
|
gptkbp:UNII
|
R7T0KZ6CMO
|
|
gptkbp:usedFor
|
gptkb:influenza_A
gptkb:influenza_B
|
|
gptkbp:bfsParent
|
gptkb:zanamivir
|
|
gptkbp:bfsLayer
|
6
|